Results 41 to 50 of about 32,062 (289)
Plasma levels of IL-1β and IL-37 in patients with severe haemophilia
Journal of International Medical Research, 2020 Objective Haemophilia A and B are disorders caused by the lack of clotting factors VIII and IX, respectively. Repeated bleeding into the same joint leads to haemophilic arthropathy (HA).
Pei-Chin Lin +7 more
doaj +1 more source
Biotechnology and Bioengineering, EarlyView.Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga +2 more
wiley +1 more source
Health and Quality of Life Outcomes, 2019 Background Health-related quality of life (HRQoL) has been brought up for decades in haemophilia patients. However, no data to date are available about HRQoL in children with haemophilia using long-term follow up data.
Heng Zhang +4 more
doaj +1 more source
, 2020 The international Haemophilia Experiences, Results and Opportunities (HERO) study assessed the psychosocial aspects of life for people with haemophilia (PWH) and their caregivers in several countries. Brazil was not included in this initiative.
Santos, Rafael B. +3 more
core +1 more source
Assessment of Joint Health Status of Haemophilia Patients in a Tertiary Care Hospital of Bangladesh
Haematology Journal of BangladeshBackground: Haemophilia is a sex-linked bleeding disorder. Affected patients suffer spontaneous or post-traumatic bleeding into various sites of the body, mainly into joints, depending on the level of coagulation factor deficiency.
Nasrin Akhter +8 more
doaj +1 more source
Novel Treatments in Haemophilia & other Bleeding Disorders: A Periodic Review 2019 – Issue 2 [PDF]
, 2019 This review is meant to provide an overview in the haemophilia therapeutic landscape from January to September 2019. Therefore this issue will solely offer quick snapshots of notable advances in existing clinical trials, initiation of new clinical ...
European Haemophilia Consortium
core
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Objective This study explores the barriers to the use of tranexamic acid (TXA) for the management of postpartum hemorrhage (PPH) and provides recommendations to improve its use. Methods We conducted a mixed‐methods assessment involving 229 healthcare professionals in Kano, Lagos, and Niger States of Nigeria.
Chukwunonso Nwaokorie +5 more
wiley +1 more source
The relationship between target joints and direct resource use in severe haemophilia
Health Economics Review, 2018 Objectives Target joints are a common complication of severe haemophilia. While factor replacement therapy constitutes the majority of costs in haemophilia, the relationship between target joints and non drug-related direct costs (NDDCs) has not been ...
Jamie O’Hara +6 more
doaj +1 more source
Dental management of patients with haemophilia
, 2021 Haemophilia is a group of hereditary disorders caused by decreased activity of clotting factors, resulting in an increased risk of haemorrhage that may be fatal if left untreated.
Abdul Majeed, Toufiq Abdul-Qadeer
core
Clinical outcome of moderate haemophilia compared with severe and mild haemophilia.
, 2020 UNLABELLED: Information on outcome and treatment of patients with moderate haemophilia is scarce. In this study, we compared self-reported burden of disease in moderate haemophilia to severe and mild haemophilia.
Van Der Bom, JG +5 more
core +1 more source